Article citationsMore>>
Du Bois, A., Floquet, A., Kim, J.W., Rau, J., Maria Del Campo, J., Friedlander, M., Pignata, S., et al. (2013) Randomized, Double-Blind, Phase III Trial of Pazopanib versus Placebo in Women Who Have Not Progressed after First-Line Chemotherapy for Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (AEOC): Results of an International Intergroup Trial (AGO-OVAR16). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31, Article ID: LBA5503.
has been cited by the following article:
-
TITLE:
Current Possible Drug Therapies for Ovarian Cancer
AUTHORS:
Jungyeob Seoung, Young-Han Park, Chaechun Rhim, Sungju Kim
KEYWORDS:
Ovarian Cancer, Intraperitoneal Chemotherapy, Targeting Therapy
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.5 No.13,
November
7,
2014
ABSTRACT:
Ovarian cancer is the most aggressive
gynecologic cancer of the heterogenous phenotypes. Development of the new
chemotherapeutic agents and drug delivery mode makes better outcomes for
patient treatments. Optimal cytoreductive therapy followed by molecular
targeting therapy, intraperitoneal chemotherapy and dose dense chemotherapy is
a hot therapeutic concept in ovarian cancers. In our review, we will introduce
recent therapeutic advances in epithelial ovarian cancer patients.
Related Articles:
-
Manfred Schmolz, Reinhard W. März, Marco Schaudt, Cornelia Schaudt, Carola Lauster
-
Patrick P. Basu, Niraj J. Shah, Hemanth Hampole, Nitya Krishnaswamy, Mark M. Aloysius
-
Md. Sahab Uddin, Abdullah Al Mamun, Md. Asaduzzaman
-
Mohit Garg, Piyush Gupta, Kevin Kang, Avichai Dukshtein, Dennis Feierman
-
Xi Wang, Zhaoxia Li, Dan Zhang, Li Li, Seite Sophie